On Friday, Biogen Inc (NASDAQ: BIIB) was -0.56% drop from the session before settling in for the closing price of $119.51. A 52-week range for BIIB has been $110.04 – $238.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -5.94%. When this article was written, the company’s average yearly earnings per share was at -6.22%. With a float of $145.62 million, this company’s outstanding shares have now reached $145.80 million.
The extent of productivity of a business whose workforce counts for 7605 workers is very important to gauge. In terms of profitability, gross margin is 78.54%, operating margin of 31.0%, and the pretax margin is 20.12%.
Biogen Inc (BIIB) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Biogen Inc stocks. The insider ownership of Biogen Inc is 0.51%, while institutional ownership is 91.53%. The most recent insider transaction that took place on Mar 07 ’25, was worth 1,314,142. In this transaction Director of this company sold 8,760 shares at a rate of $150.02, taking the stock ownership to the 11,318 shares. Before that another transaction happened on Mar 07 ’25, when Company’s Director proposed sale 8,760 for $147.37, making the entire transaction worth $1,290,961.
Biogen Inc (BIIB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.29% during the next five years compared to -18.66% drop over the previous five years of trading.
Biogen Inc (NASDAQ: BIIB) Trading Performance Indicators
You can see what Biogen Inc (BIIB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.88. Likewise, its price to free cash flow for the trailing twelve months is 6.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.18, a number that is poised to hit 2.99 in the next quarter and is forecasted to reach 15.63 in one year’s time.
Technical Analysis of Biogen Inc (BIIB)
The latest stats from [Biogen Inc, BIIB] show that its last 5-days average volume of 1.68 million was superior to 1.64 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 68.15%. Additionally, its Average True Range was 4.48.
During the past 100 days, Biogen Inc’s (BIIB) raw stochastic average was set at 15.93%, which indicates a significant decrease from 64.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.99% in the past 14 days, which was higher than the 31.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $133.65, while its 200-day Moving Average is $167.77. Now, the first resistance to watch is $119.93. This is followed by the second major resistance level at $121.01. The third major resistance level sits at $122.41. If the price goes on to break the first support level at $117.45, it is likely to go to the next support level at $116.05. The third support level lies at $114.97 if the price breaches the second support level.
Biogen Inc (NASDAQ: BIIB) Key Stats
There are 146,375K outstanding shares of the company, which has a market capitalization of 17.40 billion. As of now, sales total 9,676 M while income totals 1,632 M. Its latest quarter income was 2,455 M while its last quarter net income were 266,700 K.
